US Alzheimer Drug Pipeline Analysis

In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged
65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like
heart disease have decreased, the death due to Alzheimer's have increased by more than 60%
between 2000 and 2012. The total number of patients having Alzheimers disease was 5.4
million in 2012. Out of this, the people aged 65 and above accounted for 5.2 million and at
least 200,000 patients were younger than 65 with early-onset of Alzheimers. It has been
observed that almost 1 in 8 people coming under the 65+ age group are patients of Alzeimers
disease. Amongst the population in the 80+ age group, almost 45% have been detected with
Alzeimers disease.
There exists strong competition in the Azheimers disease market in the US. Due to this, the
market is open to new and savvy companies. Given that there is a continuous rise in the
ageing population and an expected exponential increase in Alzheimers disease cases, these
new entrants have the opportunity to capture a major share in the market through their
efficient therapies and drugs. Thus, a better understanding of the underlying biology by the
new entrants would lead to many new branches of treatment in different stages of clinical
testing.
US Alzheimer Drug Pipeline Analysis by PNS Pharma gives comprehensive insight on the
various vaccines being developed for the treatment of multiple cancers. Research report
covers all the ongoing vaccines being developed in various development phases. This report
enables pharmaceutical companies, collaborators and other associated stake holders to
identify and analyze the available investment opportunity in the cancer vaccine market based
upon development process.
For Report Sample Contact: rajesh@pnspharma.com
Following parameters for each vaccine profile in development phase are covered in US
Alzheimer Drug Pipeline Analysis research report:
Drug Profile Overview
Alternate Names for Drug
Active Indication
Phase of Development
Mechanism of Action
Brand Name
Patent Information
Country for Clinical Trial
Owner / Originator/ Licensee/Collaborator
Administrative Route
Drug Class
ATC Codes

US Alzheimer Drug Pipeline by Clinical Phase:
Research: 28
Preclinical: 106
Phase 0: 3
Phase-I: 36
Phase-I/II: 2
Phase-II: 25
Phase-II/III: 3
Phase-III: 8
Preregistration: 2
Marketed: 6
For Report Sample Contact: rajesh@pnspharma.com
Each Drug Profile has Tables Representing Following Information:
Alternate Names
Originator & Owner
Collaborator
Technology Provider
Licensee
Highest Development Phase
Indications
Class
Mechanism of Action
ATC Code
Designated Brand Name